Acute Ischemic Stroke Therapeutics Market: Growth Opportunities led by Athersys Inc. and Bayer AG - Technavio - Yahoo Finance

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The acute ischemic stroke (AIS) therapeutics market size is estimated to grow by USD 1,524.49 million during 2022-2027, at a CAGR of 5.72%. The growth of the market will be driven by the rising prevalence of high-risk factors. Furthermore, the use of technologies such as TBI is expected to boost market growth.

Technavio has announced its latest market research report titled Global Acute Ischemic Stroke Therapeutics Market 2023-2027

Technavio has announced its latest market research report titled Global Acute Ischemic Stroke Therapeutics Market 2023-2027

The report extensively covers the acute ischemic stroke (AIS) therapeutics market segmentation by type (thrombolytic, anticoagulants, antiplatelets, and antihypertensives), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW). Request a Free Sample Report

Acute Ischemic Stroke Therapeutics Market - Vendors

The global AIS therapeutics market is a fragmented market, with the presence of various large and small players. Large players are focusing on consolidating the market through increased strategic alliances and acquisitions to increase their market shares. In addition, these vendors are continuously innovating their offerings. Some of the key vendors are listed below:

  • Athersys Inc.

  • Bayer AG

  • Biogen Inc.

  • Boehringer Ingelheim International GmbH

  • Medtronic Plc

  • NoNO Inc.

  • SanBio Co Ltd.

  • Stryker Corp.

  • Amgen Inc.

  • AstraZeneca Plc

  • Bristol Myers Squibb Co.

  • Daiichi Sankyo Co. Ltd.

  • F. Hoffmann La Roche Ltd.

  • Johnson & Johnson

  • Merck & Co. Inc.

  • Sanofi SA

  • Teva Pharmaceutical Industries Ltd.

Product Insights and News

• athersys.com: The company offers acute ischemic stroke therapeutics such as Repatha.

bayer.com - The company offers acute ischemic stroke therapeutics such as BRILINTA ticagrelor tablets.

biogen.com - The company offers acute ischemic stroke therapeutics such as Masters 2 MultiStem cell therapy.

For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report.

Acute Ischemic Stroke Therapeutics Market - Geographical Landscape

North America is estimated to account for 38% of the market's growth during the forecast period. The growth of the market in this region is attributed to factors such as the expected approval of late-stage pipeline molecules, including BIIB093 (intravenous glibenclamide), BRILINTA, MultiStem, and NA-1. In addition, the region is expected to witness the availability of various diagnostics and drugs for the treatment of stroke, which will drive market growth.

 Acute Ischemic Stroke Therapeutics Market - Market Segmentation

The thrombolytics segment is estimated to contribute the highest share of the global market's growth during the forecast period. One of the factors behind the growth of this segment is the availability of US FDA-approved therapeutic treatments for AIS. For instance, the IV alteplase drug is sold under the brand name Activase. It is a tissue plasminogen activator and is used for multiple indications such as AIS, acute myocardial infarction (AMI), and acute massive pulmonary embolism (PE). Download a free sample report

What are the key data covered in this acute ischemic stroke (AIS) therapeutics market report?

  • CAGR of the market during the forecast period

  • Detailed information on factors that will drive the growth of the acute ischemic stroke (AIS) therapeutics market between 2023 and 2027

  • Precise estimation of the size of the acute ischemic stroke (AIS) therapeutics market size and its contribution to the parent market

  • Accurate predictions about upcoming trends and changes in consumer behavior

  • Growth of the acute ischemic stroke (AIS) therapeutics market across APAC, North America, Europe, Middle East and Africa, and South America

  • Thorough analysis of the market's competitive landscape and detailed information about vendors

  • Comprehensive analysis of factors that will challenge the growth of acute ischemic stroke (AIS) therapeutics market vendors

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

Related Reports:

APAC Acute Myeloid Leukemia (AML) Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The acute myeloid leukemia (AML) treatment market size in APAC is projected to grow by USD 277.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.83%.

Alzheimer's Disease Therapeutics Market by Drug Class and Geography - Forecast and Analysis 2022-2026: The Alzheimer's disease therapeutics market size is projected to grow by USD 3.99 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.76%.

Acute Ischemic Stroke Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2022

Historic Period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.72%

Market growth 2023-2027

USD 1524.49 million

Market structure

Fragmented

YoY growth (%)

5.49

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, UK, Germany, and China

Competitive landscape

Leading companies, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Companies profiled

Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Medtronic Plc, NoNO Inc., SanBio Co Ltd., Stryker Corp., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.

Market Dynamics

Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and slow-growing segment analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio "Health Care" Research Reports

Table of Contents

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition

  • 3.3 Market size 2022

4 Five Forces Analysis

  • 4.1 Five forces summary

  • 4.6 Threat of rivalry

  • 4.7 Market condition

5 Market Segmentation by Type

  • 5.1 Market segments

  • 5.2 Comparison by Type

6 Market Segmentation by Distribution Channel

  • 6.1 Market segments

7 Customer Landscape

8 Geographic Landscape

9 Drivers, Challenges, and Trends

  • 9.1 Market drivers

  • 9.2 Market challenges

  • 9.4 Market trends

10 Vendor Landscape

  • 10.1 Overview

  • 10.2 Vendor landscape

  • 10.4 Industry risks

11 Vendor Analysis

  • 11.1 Vendors covered

  • 11.3 Amgen Inc.

  • 11.4 AstraZeneca Plc

  • 11.5 Athersys Inc.

  • 11.6 Bayer AG

  • 11.7 Biogen Inc.

  • 11.13 Medtronic Plc

  • 11.14 Merck and Co. Inc.

  • 11.15 Pfizer Inc.

  • 11.16 Sanofi SA

12 Appendix

  • 12.1 Scope of the report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Global Acute Ischemic Stroke Therapeutics Market 2023-2027

Global Acute Ischemic Stroke Therapeutics Market 2023-2027

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/acute-ischemic-stroke-therapeutics-market-growth-opportunities-led-by-athersys-inc-and-bayer-ag---technavio-301687079.html

SOURCE Technavio

Adblock test (Why?)

Comments

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management